Federal Register / Vol. 72, No. 12 / Friday, January 19, 2007 / Notices 2529 

ESTIMATE OF ANNUALIZED BURDEN HOURS—Continued 

Form Number of 

respondents 

Number of 

responses Avg. burden 

—Salmonella (electronic) ..................................................................................................... 53 52 3/60 

—Shigella (electronic) .......................................................................................................... 53 52 3/60 

Foodborne Outbreak Form ................................................................................................... 54 25 15/60 

Arboviral Surveillance (ArboNet) .......................................................................................... 57 1421 4/60 

Influenza: 

—Influenza virus (fax, Oct–May) .......................................................................................... 8 33 10/60 

—Influenza virus (fax, year round) ....................................................................................... 15 52 10/60 

*** Influenza virus (Internet; Oct–May) ................................................................................. 13 33 10/60 

*** Influenza virus (Internet; year round) .............................................................................. 24 52 10/60 

—Influenza virus (electronic, Oct–May) ............................................................................... 9 33 5/60 

—Influenza virus (electronic, year round) ............................................................................ 14 52 5/60 

Influenza Annual Survey ...................................................................................................... 83 1 15/60 

Influenza-like Illness (Oct–May) ........................................................................................... 824 33 15/60 

Influenza-like Illness (year round) ........................................................................................ 496 52 15/60 

Monthly Respiratory & Enterovirus Surveillance Report: 

—Excel format (electronic) ................................................................................................... 25 12 15/60 

National Respiratory & Enteric Virus Surveillance System (NREVSS) ............................... 90 52 10/60 

Rabies (electronic) ................................................................................................................ 50 12 8/60 

Rabies (paper) ...................................................................................................................... 3 12 15/60 

Waterborne Diseases Outbreak Form ................................................................................. 57 1 20/60 

Cholera and other Vibrio illnesses ....................................................................................... 450 1 20/60 

Calicivirus surveillance (CaliciNet) ....................................................................................... 20 5 5/60 

Listeria Case Form ............................................................................................................... 53 1 30/60 

Deborah Holtzman, 

Reports Clearance Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. E7–704 Filed 1–18–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–07–07AG] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. To 

request more information on the 

proposed projects or to obtain a copy of 

the data collection plans and 

instruments, call 404–639–5960 and 

send comments to Joan F. Karr, CDC 

Acting Reports Clearance Officer, 1600 

Clifton Road, MS–D74, Atlanta, GA 

30333 or send an e-mail to 

omb@cdc.gov. 

Comments are invited on: (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

National HIV Behavioral Surveillance 

System (NHBS)—New—National Center 

for HIV, STD, and TB Prevention 

(NCHSTP), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

The purpose of this data collection is 

to monitor behaviors related to Human 

Immunodeficiency Virus (HIV) infection 

among persons at high risk for infection 

in the United States. The primary 

objectives of the system are to obtain 

data from samples of persons at risk to: 

(a) Describe the prevalence and trends 

in risk behaviors; (b) describe the 

prevalence of and trends in HIV testing 

and HIV infection; (c) describe the 

prevalence of and trends in use of HIV 

prevention services; (d) identify met and 

unmet needs for HIV prevention 

services in order to inform health 

departments, community based 

organizations, community planning 

groups and other stakeholders. This 

project addresses the goals of CDC’s HIV 

prevention strategic plan, specifically 

the goal of strengthening the national 

capacity to monitor the HIV epidemic to 

better direct and evaluate prevention 

efforts. 

Data are collected through in-person 

interviews conducted with persons 

systematically selected from 25 

Metropolitan Statistical Areas (MSAs) 

throughout the United States; these 25 

MSAs were chosen based on having 

high AIDS prevalence. Persons at risk 

for HIV infection to be interviewed for 

NHBS include men who have sex with 

men (MSM), injecting drug users (IDU), 

and heterosexual persons living in 

census tracts that have high HIV/AIDS 

prevalence (HET). A brief screening 

interview will be used to determine 

eligibility for participation in the full 

survey. The data from the full survey 

will provide estimates of behavior 

related to the risk of HIV and other 

sexually transmitted diseases, prior 

testing for HIV, and use of HIV 

prevention services. All persons 

interviewed will also be offered an HIV 

test, and will participate in a pre-test 

counseling session. No other federal 

agency systematically collects this type 

of information from persons at risk for 

HIV infection. This data will have 

substantial impact on prevention 

program development and monitoring at 

the local, state, and national levels. 

CDC estimates that NHBS will 

involve, per year in each of the 25 

MSAs, eligibility screening for 50 to 200 

persons and eligibility screening plus 

the survey and HIV testing with 500 

eligible respondents, resulting in a total 

of 37,500 eligible survey respondents 


sroberts on PROD1PC70 with NOTICES
2530 Federal Register / Vol. 72, No. 12 / Friday, January 19, 2007 / Notices 

and 7,500 ineligible screened persons 

during a 3-year period. Data collection 

will rotate such that interviews will be 

conducted among one group per year: 

MSM in year 1, IDU in year 2, and HET 

in year 3. The type of data collected for 

each group will vary slightly due to 

different sampling methods and risk 

characteristics of the group. 

Participation of respondents is 

voluntary and there is no cost to the 

respondents other than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Respondents Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

MSM: 

Screener only ........................................................................................... 5,000 1 5/60 417 

Screener, survey, and testing .................................................................. 12,500 1 65/60 13,542 

IDU: 

Screener only ........................................................................................... 1,250 1 5/60 104 

Screener, survey, and testing .................................................................. 12,500 1 90/60 18,750 

HET: 

Screener only ........................................................................................... 1,250 1 5/60 104 

Screener, survey, and testing .................................................................. 12,500 1 75/60 15,625 

Total ................................................................................................... ........................ ........................ ........................ 48,542 

Dated: January 12, 2007. 

Deborah Holtzman, 

Reports Clearance Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. E7–705 Filed 1–18–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Breast and Cervical Cancer Early 

Detection and Control Advisory 

Committee 

In accordance with section 10(a)(2)of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned 

committee meeting: 

Times and Dates: 8:30 a.m.–5 p.m., 

February 6, 2007; 8:30 a.m.–3 p.m., February 

7, 2007. 

Place: Centers for Disease Control and 

Prevention, 1600 Clifton Road, NE., Tom 

Harkin Global Community Center, Building 

19, Atlanta, Georgia 30333, Telephone: 404–

639–1717. 

Status: Open to the public, limited only by 

the space available. 

Purpose: The committee is charged with 

advising the Secretary, Department of Health 

and Human Services, and the Director, CDC, 

regarding the early detection and control of 

breast and cervical cancer. The committee 

makes recommendations regarding national 

program goals and objectives; 

implementation strategies; and program 

priorities including surveillance, 

epidemiologic investigations, education and 

training, information dissemination, 

professional interactions and collaborations, 

and policy. 

Matters to be Discussed: The agenda will 

include a review and discussion of the 

National Breast and Cervical Cancer Early 

Detection Program components; and 

discussion and review of related policies and 

emerging issues. 

Agenda items are subject to change as 

priorities dictate. 

Contact Person for More Information: 

Debra Younginer, Executive Secretary, 

BCCEDCAC, Division of Cancer Prevention 

and Control, National Center for Chronic 

Disease Prevention and Health Promotion, 

CDC, 4770 Buford Highway, Mailstop K–57, 

Chamblee, Georgia 30316, Telephone: 770–

488–1074. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities for 

both CDC and NCEH/ATSDR. 

Dated: January 12, 2007. 

Edward Schultz, 

Acting Director, Management Analysis and 

Services Office, Center for Disease Control 

and Prevention. 

[FR Doc. E7–721 Filed 1–18–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Clinical Laboratory Improvement 

Advisory Committee 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following committee 

meeting. 

Name: Clinical Laboratory Improvement 

Advisory Committee (CLIAC). Web site: 

http://www.phppo.cdc.gov/CLIAC/ 

default.aspx. 

Times and Dates: 8:30 a.m.–5 p.m., 

February 14, 2007; 8:30 a.m.–3 p.m., 

February 15, 2007. 

Place: Omni Hotel at CNN Center, 100 

CNN Center, Atlanta, Georgia 30303; Phone: 

(404) 659–0000, Fax: (404) 525–5050 (http:// 

www.omnihotels.com/FindAHotel/ 

AtlantaCNNCenter.aspx). 

Status: Open to the public, limited only by 

the space available. The meeting room 

accommodates approximately 100 people. 

Purpose: This committee is charged with 

providing scientific and technical advice and 

guidance to the Secretary of Health and 

Human Services, the Assistant Secretary for 

Health, and the Director, CDC, regarding the 

need for, and the nature of, revisions to the 

standards under which clinical laboratories 

are regulated, the impact on medical and 

laboratory practice of proposed revisions to 

the standards, and the modification of the 

standards to accommodate technological 

advances. 

Matters to be Discussed: The agenda will 

include updates from the CDC, the Centers 

for Medicare & Medicaid Services, and the 

Food and Drug Administration; discussion of 

the status of the ‘‘Notice of Proposed 

Rulemaking’’ for genetic testing; 

presentations and discussion concerning the 

future of health laboratory practice 

specifically focusing on simple testing in 

diverse sites; reports and discussions 

addressing the impact of the Morbidity and 

Mortality Weekly Report (MMWR) 

Publication of ‘‘Good Laboratory Practices for 

Waived Testing Sites’’; a report from the 

CLIAC Workgroup on ‘‘The Impact of Rapid 

and Molecular Tests for Infectious Disease 

Agents on Public Health’’ and discussion of 

the workgroup’s proposals related to such; 

and presentations and discussion concerning 

rapid HIV testing. Agenda items are subject 

to change as priorities dictate. 

Providing Oral or Written Comments: It is 

the policy of CLIAC to accept written public 

comments and provide a brief period for oral 

public comments whenever possible. 


sroberts on PROD1PC70 with NOTICES